Social Items

LONDON (Reuters) - A new drug that halts the function of a gene lowers bad cholesterol by 59 percent if mixed with other cholesterol reducers and reduces the incidence of heart attacks, British newspapers The Telegraph and Times reported on Monday. A global trial of 27,000 people in 49 countries Said that those who take the drug Ivolukumab - which inhibits the action of the gene called "PCSK 9" - have low levels of bad cholesterol up to 60% sometimes, if they take with him other cholesterol reduction known. The results of the study - published in the magazine " New York Journal of Medicine - Evolucumab also reduces heart attack by 25%, and has no side effects. Evolucumab differs from cholesterol reducers in that it stops the work of the gene "PCSK 9", which hampers the ability of the liver to clean the blood from "This is one of the most important trials to lower cholesterol since the start of these reductions 20 years ago," said Professor Peter Surfer, a professor at the Imperial College London University. "The study was described before the annual meeting of the American College The College of Cardiology in Washington yesterday as a major breakthrough, and described the drug Evolokomab as a highly effective and safe and adds a new dimension to patients "suffering from the most deadly diseases of human forces" in the Western world. The number of deaths in coronary artery disease alone in Britain is 73 An average of 2,000 per year, and that the cost of EVOLOCOMAB is £ 4,500 per patient per year.

source

New breakthrough in the fight against harmful cholesterol

LONDON (Reuters) - A new drug that halts the function of a gene lowers bad cholesterol by 59 percent if mixed with other cholesterol reducers and reduces the incidence of heart attacks, British newspapers The Telegraph and Times reported on Monday. A global trial of 27,000 people in 49 countries Said that those who take the drug Ivolukumab - which inhibits the action of the gene called "PCSK 9" - have low levels of bad cholesterol up to 60% sometimes, if they take with him other cholesterol reduction known. The results of the study - published in the magazine " New York Journal of Medicine - Evolucumab also reduces heart attack by 25%, and has no side effects. Evolucumab differs from cholesterol reducers in that it stops the work of the gene "PCSK 9", which hampers the ability of the liver to clean the blood from "This is one of the most important trials to lower cholesterol since the start of these reductions 20 years ago," said Professor Peter Surfer, a professor at the Imperial College London University. "The study was described before the annual meeting of the American College The College of Cardiology in Washington yesterday as a major breakthrough, and described the drug Evolokomab as a highly effective and safe and adds a new dimension to patients "suffering from the most deadly diseases of human forces" in the Western world. The number of deaths in coronary artery disease alone in Britain is 73 An average of 2,000 per year, and that the cost of EVOLOCOMAB is £ 4,500 per patient per year.

source
health & beauty

No comments

Subscribe to: Post Comments (Atom)